These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26054673)

  • 1. Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters.
    Chun SY; Kwon YS; Nam KS; Kim S
    Biomed Pharmacother; 2015 May; 72():37-43. PubMed ID: 26054673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
    Kwon YS; Chun SY; Nam KS; Kim S
    Oncol Rep; 2015 Aug; 34(2):884-90. PubMed ID: 26063481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
    Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
    Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
    Li Y; Zhai Z; Li H; Wang X; Huang Y; Su X
    Chem Biol Interact; 2019 May; 305():98-104. PubMed ID: 30929998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
    Vannini I; Zoli W; Fabbri F; Ulivi P; Tesei A; Carloni S; Brigliadori G; Amadori D
    Anticancer Drugs; 2009 Nov; 20(10):918-25. PubMed ID: 19752719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters.
    Li K; Lai H
    Biomed Pharmacother; 2017 Dec; 96():371-377. PubMed ID: 29028589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
    Chaisit T; Siripong P; Jianmongkol S
    Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial acquisition of stemness properties in tumorspheres obtained from interleukin-8-treated MCF-7 cells.
    Ospina-Muñoz N; Vernot JP
    Tumour Biol; 2020 Dec; 42(12):1010428320979438. PubMed ID: 33325322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
    Zheng X; Cui D; Xu S; Brabant G; Derwahl M
    Int J Oncol; 2010 Aug; 37(2):307-15. PubMed ID: 20596658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2013 Mar; 13(1):33-47. PubMed ID: 22948710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
    Minami T; Kijima T; Otani Y; Kohmo S; Takahashi R; Nagatomo I; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
    Mol Cancer Ther; 2012 Apr; 11(4):830-41. PubMed ID: 22389470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.